China Resources Pharmaceutical (03320) issued an announcement. The bidding process for the proposed subscription items expired on December 25, 2023, and China Resources Pharmaceutical entered into a subscription agreement with Beijing Pharmaceutical, China Resources Pharmaceutical Investment and investor subscribers on December 28, 2023. According to this, China Resources Pharmaceutical Commercial has agreed to increase its registered capital from RMB 15 billion to RMB 4.646.5 billion to RMB 19.646.5 billion, of which the investor subscribers have agreed to subscribe for the total registered capital of RMB 3.04 billion, with a total cost of RMB 5.26 billion Yuan, and Beijing Pharmaceutical and China Resources Pharmaceutical Investment (as existing shareholder subscribers) have agreed to subscribe for a total additional registered capital of RMB 742 million, at a total cost of RMB 1 billion.
Investor subscribers refer to Jianxin Financial Asset Investment Co., Ltd., Agricultural Bank Financial Asset Investment Co., Ltd., ICBC Financial Asset Investment Co., Ltd., BOC Financial Asset Investment Co., Ltd., Beijing Guorui Zhongxin Equity Investment Fund (limited partnership), and Beijing People's Insurance Health and Pension Industry Investment Fund (limited partnership).